ALK-Positive Lung Non-Small Cell Carcinoma

ALK-Positive Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 10
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Guangdong Association of Clinical Trials
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04211922	Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib	terminated	Phase 2	4	Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY	1	Apr 26, 2024	clinicaltrials
NCT02513667	Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma	terminated	Phase 2	14	University of Texas Southwestern Medical CenterOTHER	1	Feb 3, 2023